Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
about
Glycobiology simplified: diverse roles of glycan recognition in inflammationDevelopment of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System.Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophagesAspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.Cell membrane-derived nanomaterials for biomedical applications.Possible role of sialylation of retinal protein glycans in the regulation of electroretinogram response in mice.SAMP-ending down sepsis.Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management.Sialic Acids in the Immune Response during Sepsis.Emerging nanomedicine applications and manufacturing: progress and challenges.Polysialylation and lipopolysaccharide-induced shedding of E-selectin ligand-1 and neuropilin-2 by microglia and THP-1 macrophages.Expression of Siglec-E Alters the Proteome of Lipopolysaccharide (LPS)-Activated Macrophages but Does Not Affect LPS-Driven Cytokine Production or Toll-Like Receptor 4 Endocytosis.Single-use membrane adsorbers for endotoxin removal and purification of endogenous polysialic acid from Escherichia coli K1.Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide.Forming next-generation antibody-nanoparticle conjugates through the oriented installation of non-engineered antibody fragments.Recent advances in nanomedicine for sepsis treatment.Microglial Lectins in Health and Neurological Diseases.Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections
P2860
Q37111287-8293C1BF-0E98-41A9-A156-3D68B4E22606Q37738234-F381432B-DA75-48A5-B72F-A623F0DEDBA3Q38676224-69AF1730-5493-4B94-B05B-24C96F0B4F9CQ38876926-AE2B9D88-454A-4493-A789-B1CCBF1A810FQ39023606-EEBD1A75-FF34-443B-8F5D-9B977CA8AC33Q39128543-00867F7C-7608-49CB-8303-560E0B803952Q39178313-2FDFDAFE-386C-42B5-9906-3489D01A5A99Q41374149-EF29770D-C288-42D9-9406-5C0EB00E5ADFQ42330827-58EEB874-E4C3-467F-8A98-FFEEE41BDC8FQ46184518-288E0B9C-A8DC-4B44-B27E-4BB94BC8D420Q47098617-6F1F77FD-1030-4C1F-BEBA-6CE543D6E22AQ47875946-E3138FC2-9626-4102-AEAA-08BB7439247FQ48756171-379CB2B8-701B-4D8C-95F9-4190375B58B0Q49209369-A3CF603F-E7DC-4257-9D1D-EB4588F6A319Q52355064-7BC77492-4ACE-49BC-A987-B6419929CB79Q52578478-668DE017-F5D2-4AF3-B0BC-A8883926D49FQ52599608-A65C09A8-F326-4AF4-8FE6-28361E5C66D7Q54222088-9F867773-5A9A-420B-A92F-9F8F337FC379Q54988763-915B1650-6D3A-48BE-95BE-D2D86AFF74CDQ55515607-BCF2B4A2-C6F3-4A34-BAED-BFC0E68FFBFBQ58693503-10E6E2D1-E44F-41F6-B74F-75CF933DD718
P2860
Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
@en
type
label
Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
@en
prefLabel
Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
@en
P2093
P2860
P50
P1476
Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation
@en
P2093
Baljinder K Bains
Christopher J Scott
Daniela Schmid
Denise C Fitzgerald
Donna M Small
Efrosyni Themistou
James A Johnston
James F Burrows
Jonathan Beck
Marianne Fitzgerald
P2860
P304
P356
10.1126/SCITRANSLMED.AAB3459
P407
P577
2015-09-01T00:00:00Z